Neuroscience Discovery, Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
Neuroscience Discovery, Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN, USA.
Biochem Pharmacol. 2018 May;151:263-281. doi: 10.1016/j.bcp.2018.01.018. Epub 2018 Jan 9.
The need for improved medications for psychiatric and neurological disorders is clear. Difficulties in finding such drugs demands that all strategic means be utilized for their invention. The discovery of forebrain specific AMPA receptor antagonists, which selectively block the specific combinations of principal and auxiliary subunits present in forebrain regions but spare targets in the cerebellum, was recently disclosed. This discovery raised the possibility that other auxiliary protein systems could be utilized to help identify new medicines. Discussion of the TARP-dependent AMPA receptor antagonists has been presented elsewhere. Here we review the diversity of protein complexes of neurotransmitter receptors in the nervous system to highlight the broad range of protein/protein drug targets. We briefly outline the structural basis of protein complexes as drug targets for G-protein-coupled receptors, voltage-gated ion channels, and ligand-gated ion channels. This review highlights heterodimers, subunit-specific receptor constructions, multiple signaling pathways, and auxiliary proteins with an emphasis on the later. We conclude that the use of auxiliary proteins in chemical compound screening could enhance the detection of specific, targeted drug searches and lead to novel and improved medicines for psychiatric and neurological disorders.
对于精神和神经疾病的治疗药物,人们的需求明显增加。由于寻找此类药物的难度较大,所以需要利用一切战略手段来进行发明创造。最近发现了一种专门针对前额叶的 AMPA 受体拮抗剂,它可以选择性地阻断前额叶区域中主要和辅助亚基的特定组合,而不会影响小脑的靶标。这一发现提出了一种可能性,即可以利用其他辅助蛋白系统来帮助确定新的药物。关于 TARP 依赖性 AMPA 受体拮抗剂的讨论已在其他地方进行。在这里,我们将回顾神经系统中神经递质受体的蛋白质复合物的多样性,以突出显示广泛的蛋白质/蛋白质药物靶标。我们简要概述了作为 G 蛋白偶联受体、电压门控离子通道和配体门控离子通道药物靶点的蛋白质复合物的结构基础。这篇综述强调了异二聚体、亚基特异性受体结构、多种信号通路和辅助蛋白,重点介绍了后者。我们得出结论,在化合物筛选中使用辅助蛋白可以增强对特定靶向药物的检测,从而为精神和神经疾病带来新的、改进的药物。